Business Context and Reporting Period
This Form 8-K Current Report was filed by Arvinas, Inc. on January 9, 2023. The filing primarily serves to disclose Regulation FD information regarding a presentation at the J.P. Morgan 41st Annual Healthcare Conference and to provide updated guidance on clinical development programs, specifically the collaboration with Pfizer Inc. on ARV-471.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on clinical trial updates and regulatory guidance.
Material Changes and Clinical Updates
VERITAC-3 Phase 3 Study (ARV-471 + Palbociclib)
- Protocol Modification: Arvinas and Pfizer proposed a modification to the VERITAC-3 Phase 3 study protocol for first-line metastatic ER+/HER2- breast cancer following an analysis of Phase 1b data.
- Pharmacokinetic Findings: An approximate 50% increase in mean palbociclib exposure was observed in the fed state compared to historical fasted data.
- Safety Observations: Grade 3/4 neutropenia occurred in 76% of patients receiving 200 mg ARV-471 with 125 mg palbociclib. These events were manageable with standard dose reductions, and no increase in infection rates was reported relative to historical palbociclib studies.
- Regulatory Action: The companies requested a meeting with the FDA to review the proposed protocol update to determine the optimal palbociclib dose.
- Timeline: Pending FDA agreement, enrollment is expected to initiate in the second half of 2023.
Other Program Updates
- VERITAC-2: Phase 3 pivotal trial for second-line treatment is actively recruiting.
- TACTIVE-U: Phase 1b trial with ARV-471 in combination with ribociclib and abemaciclib was initiated in two arms in Q4 2022.
- ARV-471 Adjuvant: A Phase 3 trial in the adjuvant setting is expected to be initiated.
- bavdegalutamide (ARV-110): A pivotal trial for metastatic castration-resistant prostate cancer is expected to initiate in the second half of 2023.
- ARV-766: Phase 1 dose escalation data is expected in the second quarter of 2023.
- IND/CTA Submissions: Applications for BCL6 and LRRK2 PROTAC degraders are expected in the second half of 2023.
Guidance, Outlook, and Risks
Management provided specific timelines for upcoming clinical milestones, including data readouts in Q2 2023 and study initiations in H2 2023. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks such as the success of the collaboration with Pfizer, regulatory approvals, and the sufficiency of cash resources to fund operations.
Investor Verification Checklist
- Confirm the outcome of the FDA meeting regarding the VERITAC-3 protocol amendment.
- Monitor the initiation date of the VERITAC-3 enrollment to ensure it aligns with the H2 2023 target.
- Review the Q2 2023 data presentation for the ARV-471 and palbociclib Phase 1b combination trial.
- Verify the company's cash runway and capital requirements in subsequent filings (e.g., 10-K or 10-Q) as this 8-K does not provide liquidity data.
- Track the progress of the TACTIVE-U trial and the initiation of the ARV-110 pivotal trial.